Vbspharma.com - Vbs Pharmaceuticals Company News Section
Vbs Pharmaceuticals Information
Vascular BioSciences, a biomedical company with operations in Research Triangle, NC, San Diego, and Goleta, CA, makes interventional catheters to obtain pulmonary endoarterial biopsies, provides molecular diagnostic services, and through it's majority-owned subsidiary, VBS Pharmaceuticals, advances targeted therapies in order to enhance and prolong human life.
For more information please visit: www.vascularbiosciences.com & www.vbspharma.com.
Vascular BioSciences announces the publication of "Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension" to the current issue of the Pulmonary Circulation, Volume 3, Number 1, January to March 2013. Details how percutaneous pulmonary endoarterial biopsy coupled with histologic and molecular analysis represents a potential model of diagnosis.
Vascular BioSciences announces CEO David Mann will present "CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy" during the 7th Annual Therapeutic Peptide Symposium to be hosted at The Salk Institute in La Jolla, CA on October 25th and 26th, 2012.
VBS announces the publication of a scientific article which describes the use of an experimental endoarterial biopsy catheter to describe the hemodynamic, angiographic, and histologic progression of an aortopulmonary shunt model of PAH.
A recently published paper from Vascular Biosciences (VBS) has been selected by the Faculty of 1000 (F1000) as one of the top 2 percent of all published articles in the biological and medical sciences in 2011.
VBS Pharmaceuticals announces the publication of a peer-reviewed scientific article that describes a novel peptide that specifically targets and penetrates the vasculature of lungs affected by pulmonary arterial hypertension (PAH) in the current issue of the American Journal of Pathology.